Ken Iwai
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
Papers in
-
- Cancer, Hypoxia, and Metabolism 5
- Cancer, Lipids, and Metabolism 2
-
- Hepatocellular Carcinoma Treatment and Prognosis 4
- Co-authors
- Toshimitsu Konno (4 shared papers)Hiroshi Maeda (1 shared paper)Shôjirô Maki (4 shared papers)Seiki Tashiro (2 shared papers)Hiroshi Maeda (2 shared papers)Takehisa Hiraoka (2 shared papers)Ikuzō Yokoyama (3 shared papers)Tetsuo Morinaga (2 shared papers)
- Journals
- Cancer (1 paper)Bioscience Biotechnology and Biochemistry (1 paper)British journal of surgery (1 paper)Behavioral Sciences (1 paper)PubMed (4 papers)
- Partner nations
- JapanBangladesh
In The Last Decade
Ken Iwai
10 papers receiving 751 citations
Peers
Comparison fields: 5 of 63
- Hepatology 331
- Biomaterials 206
- Cancer Research 165
- Biophysics 44
- Oncology 143
Countries citing papers authored by Ken Iwai
This map shows the geographic impact of Ken Iwai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Iwai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Iwai more than expected).
Fields of papers citing papers by Ken Iwai
This network shows the impact of papers produced by Ken Iwai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Iwai. The network helps show where Ken Iwai may publish in the future.
Co-authors
The 25 scholars most cited alongside Ken Iwai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1983 | 264 | |
| 2 | Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. | 1984 | 234 |
| 3 | 1984 | 182 | |
| 4 | 1984 | 80 | |
| 5 | [Use of a lipid lymphographic agent, lipiodol, as a carrier of high molecular weight antitumor agent, smancs, for hepatocellular carcinoma]. | 1982 | 11 |
| 6 | 2014 | 3 | |
| 7 | [Tumor selective drug delivery with lipid contrast medium (smancs/lipiodol): sustained antitumor effect, enhanced diagnostic value and quantification of dosage regimen]. | 1984 | 3 |
| 8 | 2023 | 2 | |
| 9 | 1986 | 2 | |
| 10 | [CT image of the liver cancer after administration of SMANCS/lipiodol]. | 1986 | 1 |
About Ken Iwai
Ken Iwai is a scholar working on Cancer Research, Hepatology, Molecular Biology, Radiology, Nuclear Medicine and Imaging and Biotechnology, having authored 10 papers that have together received 782 indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Cancer, Lipids, and Metabolism (2 papers), Cancer Research and Treatments (2 papers), Lanthanide and Transition Metal Complexes (1 paper), Angiogenesis and VEGF in Cancer (1 paper), Click Chemistry and Applications (1 paper) and Free Will and Agency (1 paper). The work is most often cited by research in Hepatology (331 citations), Biomaterials (206 citations), Cancer Research (165 citations), Biophysics (44 citations) and Oncology (143 citations). Ken Iwai has collaborated with scholars based in Japan and Bangladesh. Frequent co-authors include Toshimitsu Konno, Hiroshi Maeda, Shôjirô Maki, Seiki Tashiro, Hiroshi Maeda, Takehisa Hiraoka, Ikuzō Yokoyama, Tetsuo Morinaga, Mizuho Mochinaga and Hiroshi Maeda. Their work appears in journals such as Cancer, Bioscience Biotechnology and Biochemistry, British journal of surgery, Behavioral Sciences and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.